238 related articles for article (PubMed ID: 33597645)
41. Identification of Potent
Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
[TBL] [Abstract][Full Text] [Related]
42. The atherogenic actions of LPC on vascular smooth muscle cells and its LPA receptor mediated mechanism.
Bao L; Qi J; Wang YW; Xi Q; Tserennadmid T; Zhao PF; Qi J; Damirin A
Biochem Biophys Res Commun; 2018 Sep; 503(3):1911-1918. PubMed ID: 30064908
[TBL] [Abstract][Full Text] [Related]
43. Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases.
Herr DR; Chew WS; Satish RL; Ong WY
Mol Neurobiol; 2020 Jan; 57(1):372-392. PubMed ID: 31364025
[TBL] [Abstract][Full Text] [Related]
44. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension.
Saga H; Ohhata A; Hayashi A; Katoh M; Maeda T; Mizuno H; Takada Y; Komichi Y; Ota H; Matsumura N; Shibaya M; Sugiyama T; Nakade S; Kishikawa K
PLoS One; 2014; 9(4):e93230. PubMed ID: 24747415
[TBL] [Abstract][Full Text] [Related]
45. Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate.
Madan D; Ferguson CG; Lee WY; Prestwich GD; Testa CA
PLoS One; 2013; 8(11):e79065. PubMed ID: 24278115
[TBL] [Abstract][Full Text] [Related]
46. Autotaxin in liver fibrosis.
Ikeda H; Yatomi Y
Clin Chim Acta; 2012 Nov; 413(23-24):1817-21. PubMed ID: 22820036
[TBL] [Abstract][Full Text] [Related]
47. Decrease in circulating autotaxin by oral administration of prednisolone.
Sumida H; Nakamura K; Yanagida K; Ohkawa R; Asano Y; Kadono T; Tamaki K; Igarashi K; Aoki J; Sato S; Ishii S; Shimizu T; Yatomi Y
Clin Chim Acta; 2013 Jan; 415():74-80. PubMed ID: 23063960
[TBL] [Abstract][Full Text] [Related]
48. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.
Hama K; Aoki J; Fukaya M; Kishi Y; Sakai T; Suzuki R; Ohta H; Yamori T; Watanabe M; Chun J; Arai H
J Biol Chem; 2004 Apr; 279(17):17634-9. PubMed ID: 14744855
[TBL] [Abstract][Full Text] [Related]
49. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
Gotoh M; Fujiwara Y; Yue J; Liu J; Lee S; Fells J; Uchiyama A; Murakami-Murofushi K; Kennel S; Wall J; Patil R; Gupte R; Balazs L; Miller DD; Tigyi GJ
Biochem Soc Trans; 2012 Feb; 40(1):31-6. PubMed ID: 22260662
[TBL] [Abstract][Full Text] [Related]
50. Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation.
Park GY; Lee YG; Berdyshev E; Nyenhuis S; Du J; Fu P; Gorshkova IA; Li Y; Chung S; Karpurapu M; Deng J; Ranjan R; Xiao L; Jaffe HA; Corbridge SJ; Kelly EA; Jarjour NN; Chun J; Prestwich GD; Kaffe E; Ninou I; Aidinis V; Morris AJ; Smyth SS; Ackerman SJ; Natarajan V; Christman JW
Am J Respir Crit Care Med; 2013 Oct; 188(8):928-40. PubMed ID: 24050723
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of autotaxin by bile salts and bile salt-like molecules increases its expression by feedback regulation.
Langedijk JAGM; Tolenaars D; Bolier R; Lee YT; Meurs A; Williamson C; Adorini L; van de Graaf SFJ; Beuers U; Elferink RO
Biochim Biophys Acta Mol Basis Dis; 2021 Nov; 1867(11):166239. PubMed ID: 34389475
[TBL] [Abstract][Full Text] [Related]
52. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
53. Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells.
Zhang Y; Chen YC; Krummel MF; Rosen SD
J Immunol; 2012 Oct; 189(8):3914-24. PubMed ID: 22962684
[TBL] [Abstract][Full Text] [Related]
54. Autotaxin--an LPA producing enzyme with diverse functions.
Nakanaga K; Hama K; Aoki J
J Biochem; 2010 Jul; 148(1):13-24. PubMed ID: 20495010
[TBL] [Abstract][Full Text] [Related]
55. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Samadi N; Gaetano C; Goping IS; Brindley DN
Oncogene; 2009 Feb; 28(7):1028-39. PubMed ID: 19079345
[TBL] [Abstract][Full Text] [Related]
56. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
Okudaira S; Yukiura H; Aoki J
Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
[TBL] [Abstract][Full Text] [Related]
57. Discovery of potent inhibitors of the lysophospholipase autotaxin.
Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
[TBL] [Abstract][Full Text] [Related]
58. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
[TBL] [Abstract][Full Text] [Related]
59. Autotaxin-LPA-LPP3 Axis in Energy Metabolism and Metabolic Disease.
Jose A; Kienesberger PC
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502491
[TBL] [Abstract][Full Text] [Related]
60. Pharmacological characterization of lysophosphatidic acid-induced pain with clinically relevant neuropathic pain drugs.
Ogawa K; Takasu K; Shinohara S; Yoneda Y; Kato A
Eur J Pain; 2012 Aug; 16(7):994-1004. PubMed ID: 22337641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
